01—Abstract
Summary
Summary of the 10-Q filed April 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Humana Inc. reported first-quarter 2025 net income attributable to Humana of $1.244 billiona, or $10.30 per diluted common share, compared with $741 million, or $6.11 per diluted share, in the first quarter of 2024.
Total revenues rose 8.4% to $32.112 billionb, driven by premiums revenue of $30.514 billion (up 8.0%), primarily due to higher per member Medicare premiums, largely from an increased direct subsidy under the Inflation Reduction Act, and growth in state-based contracts and stand-alone PDP membership. Income from operations increased 62.9% to $2.014 billion. The filing attributes the results partly to put/call valuation adjustments tied to non-consolidating minority interest investments and charges from value creation initiatives, which the company says significantly affected comparisons.
The benefit ratio improved to 87.0% from 88.9%, while the operating cost ratio rose to 10.6% from 10.4%. The balance sheet strengthened in liquidity terms: cash and cash equivalents rose to $4.250 billionc from $2.221 billion at December 31, 2024, and total debt increased with long-term debt reaching $12.729 billion after $1.481 billion in net proceeds from March 2025 senior note issuances used to repay $577 million of notes due April 2025. Operating cash flow was $331 million, down from $423 million, reflecting unfavorable working capital items.
Management notes that Medicare receivables rose due to the IRA subsidy and that its authorized share repurchase capacity was $2.9 billiond as of April 29, 2025, with no open-market repurchases in the quarter. The filing also discloses material legal and regulatory exposure. Humana is litigating the CMS Final RADV Rule, which eliminated the FFS Adjuster and could have a material adverse effect, and has sued over the 2025 Star Ratings.
A securities class action and related derivative suits are pending, and the company faces ongoing Department of Justice information requests on Medicare Part C risk adjustment practices. Medicare represented approximately 83% of premiums and services revenue in the quarter.
02—Key points
Key Highlights
- Net income attributable to Humana was $1.244 billion, or $10.30 per diluted share, versus $741 million, or $6.11 per diluted share, a year earlier.
- Total revenues increased 8.4% to $32.112 billion, with premiums revenue up 8.0% to $30.514 billion, driven largely by higher per member Medicare premiums from an increased IRA direct subsidy.
- Income from operations rose 62.9% to $2.014 billion; the benefit ratio improved to 87.0% from 88.9%, while the operating cost ratio edged up to 10.6% from 10.4%.
- Put/call valuation adjustments on non-consolidating minority interest investments added $163 million to pre-tax income expense in the quarter, and value creation initiatives charges totaled $24 million.
- Total senior notes carrying value rose to $12.729 billion, after March 2025 issuances netting $1.481 billion used to repay $577 million of notes due April 1, 2025.
- Operating cash flow fell to $331 million from $423 million, mainly due to unfavorable working capital items, while cash and cash equivalents increased to $4.250 billion.
- Pending litigation includes the challenge to the CMS Final RADV Rule, a lawsuit over 2025 Star Ratings, and a securities class action, each of which the filing says could have a material adverse effect if unfavorable.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed April 30, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $32.11B$29.61B | +8.4% |
| SG&A Expenses | $3.38B$3.04B | +11.1% |
| Operating Income | $2.01B$1.24B | +62.9% |
| Net Income | $1.24B$741.00M | +67.9% |
| EPS (Basic) | $10.31$6.13 | +68.2% |
| EPS (Diluted) | $10.30$6.11 | +68.6% |
| Shares Outstanding (Basic) | 120.67M120.98M | −0.3% |
| Shares Outstanding (Diluted) | 120.84M121.27M | −0.3% |
05—Questions
Frequently Asked Questions
How did Humana's profitability change in the first quarter of 2025?
Net income attributable to Humana was $1.244 billion, or $10.30 per diluted share, compared with $741 million, or $6.11 per diluted share, in the first quarter of 2024. Income from operations increased 62.9% to $2.014 billion, and the company notes that put/call valuation adjustments and value creation charges significantly affected the comparison.
What drove the increase in revenue?
Premiums revenue increased $2.3 billion, or 8.0%, to $30.5 billion, primarily due to higher per member Medicare premiums driven largely by an increased direct subsidy from the Inflation Reduction Act, as well as higher state-based contracts premiums and membership growth in stand-alone PDP and state-based contracts businesses. Services revenue increased 25.6% to $1.3 billion, mainly from growth in the primary care business.
How did the benefit ratio change, and what affected it?
The consolidated benefit ratio decreased to 87.0% from 88.9%, primarily due to individual Medicare Advantage pricing including plan exits, benefit design changes, and favorable workday impacts. Prior-period favorable reserve development was $477 million in the 2025 quarter, compared with $535 million in the 2024 quarter.
What is Humana's liquidity and debt position?
Cash and cash equivalents rose to $4.250 billion at March 31, 2025 from $2.221 billion at December 31, 2024. Long-term debt increased to $12.729 billion, and the company had no commercial paper borrowings and no revolver borrowings outstanding. The company reports remaining repurchase authorization of $2.9 billion as of April 29, 2025.
What legal and regulatory risks does the filing highlight?
Humana has sued to set aside the CMS Final RADV Rule, which eliminated the FFS Adjuster and could have a material adverse effect, and has sued over its 2025 Star Ratings. It also faces a securities class action and related derivative suits, and continues to cooperate with Department of Justice information requests on Medicare Part C risk adjustment practices. The company states it cannot predict the outcomes.
06—Continue